Surgical microwave ablation of otherwise non-resectable colorectal cancer liver metastases: Expanding opportunities for long term survival

Colorectal liver metastases (CRLM) are the most common extra-lymphatic metastases in colorectal cancers, however, only 15–20% of these patients are candidates for resection. We reviewed our institutional experience with 135 surgical ablations for unresectable CRLM. Retrospective review of surgically...

Full description

Saved in:
Bibliographic Details
Published in:Surgical oncology 2021-03, Vol.36, p.61-64
Main Authors: McEachron, Kendall R., Ankeny, Jacob S., Robbins, Alexandria, Altman, Ariella M., Marmor, Schelomo, D'Souza, Donna, Schat, Robben, Spilseth, Benjamin, Jensen, Eric H.
Format: Article
Language:English
Subjects:
Ablation
Cancer
Cancer therapies
Catheters
Chemotherapy
Colorectal cancer
Colorectal carcinoma
Laparoscopy
Lesions
Liver
Liver cancer
Metastases
Metastasis
Microwave ablation
Patients
Surgical outcomes
Survival
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal liver metastases (CRLM) are the most common extra-lymphatic metastases in colorectal cancers, however, only 15–20% of these patients are candidates for resection. We reviewed our institutional experience with 135 surgical ablations for unresectable CRLM. Retrospective review of surgically ablated CRLM from 2009 to 2018. Patient-specific variables were obtained from the medical record. Kaplan-Meier modeling was performed for survival analyses. We ablated 135 CRLM in 36 patients over 40 procedures. Median age was 52 years and 58% of patients were male. All patients received systemic chemotherapy. The ablation procedure was completed laparoscopically in 68% of procedures. Median number of ablated lesions per patient was 2 (range 1–15). Median maximum diameter of ablated lesions was 1.9 cm (range 0.5–12.2). Median follow up of the study was 28 months. In this time, median disease-free survival was not reached. Of the 135 lesions ablated, the per-lesion recurrence rate was 6/135 (4.4%). Median overall survival was 81 months. Surgical ablation of CRLM can provide excellent local control and long-term survival outcomes in patients who may otherwise not be candidates for other liver-directed therapies.
ISSN:0960-7404
1879-3320
DOI:10.1016/j.suronc.2020.11.016